Avadel Pharmaceuticals (AVDL)
(Delayed Data from NSDQ)
$17.82 USD
+0.16 (0.91%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $17.82 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth C Momentum D VGM
Income Statements
Fiscal Year end for Avadel Pharmaceuticals PLC falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 28 | 0 | 0 | 22 | 59 |
Cost Of Goods | 1 | 0 | 0 | 6 | 12 |
Gross Profit | 27 | 0 | 0 | 17 | 47 |
Selling & Adminstrative & Depr. & Amort Expenses | 165 | 99 | 86 | 11 | 71 |
Income After Depreciation & Amortization | -138 | -99 | -86 | 6 | -24 |
Non-Operating Income | -13 | -1 | 2 | 2 | -2 |
Interest Expense | 10 | 12 | 10 | 13 | 12 |
Pretax Income | -161 | -111 | -93 | -5 | -39 |
Income Taxes | -1 | 26 | -16 | -12 | -5 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -160 | -137 | -77 | 7 | -33 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -160 | -137 | -77 | 7 | -33 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -136 | -97 | -85 | 8 | -22 |
Depreciation & Amortization (Cash Flow) | 2 | 1 | 1 | 2 | 3 |
Income After Depreciation & Amortization | -138 | -99 | -86 | 6 | -24 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 80.17 | 60.09 | 58.54 | 54.94 | 37.40 |
Diluted EPS Before Non-Recurring Items | -1.87 | -2.29 | -1.32 | -0.75 | -0.89 |
Diluted Net EPS (GAAP) | -2.00 | -2.29 | -1.32 | 0.13 | -0.89 |
Fiscal Year end for Avadel Pharmaceuticals PLC falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 19.45 | 7.01 | 1.50 | 0.00 |
Cost Of Goods | NA | 0.69 | 0.12 | 0.04 | 0.00 |
Gross Profit | NA | 18.76 | 6.90 | 1.46 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 43.66 | 42.01 | 51.00 | 28.30 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -24.90 | -35.11 | -49.54 | -28.30 |
Non-Operating Income | NA | -1.63 | 0.90 | -12.51 | 0.19 |
Interest Expense | NA | 2.35 | 1.98 | 2.30 | 3.26 |
Pretax Income | NA | -28.89 | -36.19 | -64.34 | -31.36 |
Income Taxes | NA | -0.10 | 0.09 | 0.09 | -0.58 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -28.79 | -36.27 | -64.43 | -30.78 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -28.79 | -36.27 | -64.43 | -30.78 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 89.80 | 89.38 | 77.25 | 63.89 |
Diluted EPS Before Non-Recurring Items | NA | -0.32 | -0.41 | -0.70 | -0.48 |
Diluted Net EPS (GAAP) | NA | -0.28 | -0.41 | -0.83 | -0.48 |